Severe Post-COVID-19 Organizing Pneumonia during Cancer Immunochemotherapy

A 44-year-old man developed coronavirus disease 2019 (COVID-19) pneumonia during immunochemotherapy consisting of carboplatin, paclitaxel, and pembrolizumab for non-small cell lung cancer. Low-grade fever, followed by mild hypoxemia, and febrile neutropenia, were observed, and granulocyte colony-sti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitahara, Asako, Ebihara, Akinori, Obayashi, Shohei, Horio, Yukihiro, Ono, Yoshitaka, Yoshikawa, Tomohiro, Okada, Naoki, Tanaka, Jun, Takiguchi, Hiroto, Hayama, Naoki, Ito, Yoko, Oguma, Tsuyoshi, Kuwahira, Ichiro, Asano, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107986/
https://www.ncbi.nlm.nih.gov/pubmed/35135922
http://dx.doi.org/10.2169/internalmedicine.8928-21
_version_ 1784708605346316288
author Kitahara, Asako
Ebihara, Akinori
Obayashi, Shohei
Horio, Yukihiro
Ono, Yoshitaka
Yoshikawa, Tomohiro
Okada, Naoki
Tanaka, Jun
Takiguchi, Hiroto
Hayama, Naoki
Ito, Yoko
Oguma, Tsuyoshi
Kuwahira, Ichiro
Asano, Koichiro
author_facet Kitahara, Asako
Ebihara, Akinori
Obayashi, Shohei
Horio, Yukihiro
Ono, Yoshitaka
Yoshikawa, Tomohiro
Okada, Naoki
Tanaka, Jun
Takiguchi, Hiroto
Hayama, Naoki
Ito, Yoko
Oguma, Tsuyoshi
Kuwahira, Ichiro
Asano, Koichiro
author_sort Kitahara, Asako
collection PubMed
description A 44-year-old man developed coronavirus disease 2019 (COVID-19) pneumonia during immunochemotherapy consisting of carboplatin, paclitaxel, and pembrolizumab for non-small cell lung cancer. Low-grade fever, followed by mild hypoxemia, and febrile neutropenia, were observed, and granulocyte colony-stimulating factor (G-CSF) was administered until the recovery of neutropenia, when he developed a high fever, severe hypoxemia, and hypotension accompanied by consolidation in the bilateral lungs. His conditions promptly improved after treatment including hydrocortisone and the primary and metastatic tumors remained regressed for 10 months without further treatment. Post-COVID-19 organizing pneumonia during cancer immunochemotherapy can be aggravated by immune-checkpoint inhibitors and G-CSF.
format Online
Article
Text
id pubmed-9107986
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-91079862022-05-27 Severe Post-COVID-19 Organizing Pneumonia during Cancer Immunochemotherapy Kitahara, Asako Ebihara, Akinori Obayashi, Shohei Horio, Yukihiro Ono, Yoshitaka Yoshikawa, Tomohiro Okada, Naoki Tanaka, Jun Takiguchi, Hiroto Hayama, Naoki Ito, Yoko Oguma, Tsuyoshi Kuwahira, Ichiro Asano, Koichiro Intern Med Case Report A 44-year-old man developed coronavirus disease 2019 (COVID-19) pneumonia during immunochemotherapy consisting of carboplatin, paclitaxel, and pembrolizumab for non-small cell lung cancer. Low-grade fever, followed by mild hypoxemia, and febrile neutropenia, were observed, and granulocyte colony-stimulating factor (G-CSF) was administered until the recovery of neutropenia, when he developed a high fever, severe hypoxemia, and hypotension accompanied by consolidation in the bilateral lungs. His conditions promptly improved after treatment including hydrocortisone and the primary and metastatic tumors remained regressed for 10 months without further treatment. Post-COVID-19 organizing pneumonia during cancer immunochemotherapy can be aggravated by immune-checkpoint inhibitors and G-CSF. The Japanese Society of Internal Medicine 2022-02-08 2022-04-15 /pmc/articles/PMC9107986/ /pubmed/35135922 http://dx.doi.org/10.2169/internalmedicine.8928-21 Text en Copyright © 2022 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Kitahara, Asako
Ebihara, Akinori
Obayashi, Shohei
Horio, Yukihiro
Ono, Yoshitaka
Yoshikawa, Tomohiro
Okada, Naoki
Tanaka, Jun
Takiguchi, Hiroto
Hayama, Naoki
Ito, Yoko
Oguma, Tsuyoshi
Kuwahira, Ichiro
Asano, Koichiro
Severe Post-COVID-19 Organizing Pneumonia during Cancer Immunochemotherapy
title Severe Post-COVID-19 Organizing Pneumonia during Cancer Immunochemotherapy
title_full Severe Post-COVID-19 Organizing Pneumonia during Cancer Immunochemotherapy
title_fullStr Severe Post-COVID-19 Organizing Pneumonia during Cancer Immunochemotherapy
title_full_unstemmed Severe Post-COVID-19 Organizing Pneumonia during Cancer Immunochemotherapy
title_short Severe Post-COVID-19 Organizing Pneumonia during Cancer Immunochemotherapy
title_sort severe post-covid-19 organizing pneumonia during cancer immunochemotherapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107986/
https://www.ncbi.nlm.nih.gov/pubmed/35135922
http://dx.doi.org/10.2169/internalmedicine.8928-21
work_keys_str_mv AT kitaharaasako severepostcovid19organizingpneumoniaduringcancerimmunochemotherapy
AT ebiharaakinori severepostcovid19organizingpneumoniaduringcancerimmunochemotherapy
AT obayashishohei severepostcovid19organizingpneumoniaduringcancerimmunochemotherapy
AT horioyukihiro severepostcovid19organizingpneumoniaduringcancerimmunochemotherapy
AT onoyoshitaka severepostcovid19organizingpneumoniaduringcancerimmunochemotherapy
AT yoshikawatomohiro severepostcovid19organizingpneumoniaduringcancerimmunochemotherapy
AT okadanaoki severepostcovid19organizingpneumoniaduringcancerimmunochemotherapy
AT tanakajun severepostcovid19organizingpneumoniaduringcancerimmunochemotherapy
AT takiguchihiroto severepostcovid19organizingpneumoniaduringcancerimmunochemotherapy
AT hayamanaoki severepostcovid19organizingpneumoniaduringcancerimmunochemotherapy
AT itoyoko severepostcovid19organizingpneumoniaduringcancerimmunochemotherapy
AT ogumatsuyoshi severepostcovid19organizingpneumoniaduringcancerimmunochemotherapy
AT kuwahiraichiro severepostcovid19organizingpneumoniaduringcancerimmunochemotherapy
AT asanokoichiro severepostcovid19organizingpneumoniaduringcancerimmunochemotherapy

Ejemplares similares